| ||||
| ||||
Stop sending me emails. Stop sending me emails. Stop sending me emails.
Stop sending me emails. Stop sending me emails. Stop sending me emails.
Stop sending me emails. Stop sending me emails. Stop sending me emails.
Stop sending me emails. Stop sending me emails. Stop sending me emails.
Stop sending me emails. Stop sending me emails. Stop sending me emails.
Stop sending me emails. Stop sending me emails. Stop sending me emails.
Stop sending me emails. Stop sending me emails. Stop sending me emails.
Stop sending me emails. Stop sending me emails. Stop sending me emails.
Stop sending me emails. Stop sending me emails. Stop sending me emails.
Stop sending me emails. Stop sending me emails. Stop sending me emails.
Stop sending me emails. Stop sending me emails. Stop sending me emails.
Stop sending me emails. Stop sending me emails. Stop sending me emails.
Stop sending me emails.
From:"Lillian" <firefly@islc.net> on 06/26/2000 11:12 AM GMT
Sent by: "Lillian" <firefly@islc.net>
Please respond to mol-cancer@lists.meds.com
To: "MOL" <mol-cancer@lists.meds.com>
cc: (bcc: Michael G Daly/mdaly/LSU)
Subject: [MOL] Company to test drug for immune disorders....
Friday, June 23, 2000
Company to test drug for immune disorders
NEW YORK, Jun 23 (Reuters Health) - Human Genome Sciences said on
Friday that is has received clearance from the US Food and Drug
Administration to begin human clinical trials of B-lymphocyte stimulator
(BLyS), a protein that could help sufferers of Common Variable
Immunodeficiency (CVID) and other immune disorders, including AIDS.
People with CVID are more susceptible to infection, leaving them
plagued by frequent recurrences of conditions such as pneumonia, bronchitis
and sinusitis.
The BLyS therapy is designed to address CVID patients' failure to
make normal quantities of the antibodies that help defend the body against
infection by viruses and bacteria.
The usual treatment for the condition is regular administration of
antibodies. BLyS may help to restore the body's ability to produce
antibodies on its own, according to the firm, by stimulating immune system
cells called B cells to produce antibodies, the company explained.
Only a few thousand patients in the US and Europe suffer from the
CVID, but BLyS may also prove useful in treating other immune disorders.
Preclinical studies have indicated the protein's potential as a therapy for
AIDS, as well as for immune deficiencies resulting from certain cancers and
from medical procedures such as organ transplants, the firm said. In
addition, BLyS may hold promise as a treatment to boost the function of the
immune system in elderly adults.
A spokesperson for the company told Reuters Health that the trials
are expected to be underway by late July, only about a year after the
firm's original discovery of the protein.
We invite you to take a look at our Album.
www.angelfire.com/sc/molangels/index.html
( Very informational, good tips, Molers pictures, art work and much
more....
- att1.htm
Company to test drug for immune disorders NEW YORK, Jun 23 (Reuters Health) - Human Genome Sciences said on Friday that is has received clearance from the US Food and Drug Administration to begin human clinical trials of B-lymphocyte stimulator (BLyS), a protein that could help sufferers of Common Variable Immunodeficiency (CVID) and other immune disorders, including AIDS. People with CVID are more susceptible to infection, leaving them plagued by frequent recurrences of conditions such as pneumonia, bronchitis and sinusitis. The BLyS therapy is designed to address CVID patients' failure to make normal quantities of the antibodies that help defend the body against infection by viruses and bacteria. The usual treatment for the condition is regular administration of antibodies. BLyS may help to restore the body's ability to produce antibodies on its own, according to the firm, by stimulating immune system cells called B cells to produce antibodies, the company explained. Only a few thousand patients in the US and Europe suffer from the CVID, but BLyS may also prove useful in treating other immune disorders. Preclinical studies have indicated the protein's potential as a therapy for AIDS, as well as for immune deficiencies resulting from certain cancers and from medical procedures such as organ transplants, the firm said. In addition, BLyS may hold promise as a treatment to boost the function of the immune system in elderly adults. A spokesperson for the company told Reuters Health that the trials are expected to be underway by late July, only about a year after the firm's original discovery of the protein. |
|